Christine Hann, MD, PhD
Basic profileAssociate Professor of Oncology · Johns Hopkins University
Christine Hann is Associate Professor of Oncology at Johns Hopkins University. OpenAlex indexes 542 publications with 14,888 citations (h-index 53); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Updated 23 Oct 2026
Christine Hann, M.D., PH.D., is Associate Professor of Oncology at Johns Hopkins School of Medicine. The public record shows 542 publications with 14,920 citations (h-index 53), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Genomics and Diagnostics. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 8 companies, 2 NIH-funded awards (2015–2022).
- Most recent indexed publication: 2026 · Molecular cancer therapeutics
- Top research focus: Lung Cancer Treatments and Mutations
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 98.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
401 N Broadway St
Baltimore, MD 21287-0019
Telephone
410-955-8893Registry record last updated 7 Feb 2013 · collected 28 Jul 2026.
Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 23 Oct 2026
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- ABBVIE INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
53.1%Phenothiazine53.1%Prochlorperazine Maleate100%Part D≥14 patientsSensory organs
46.9%Corticosteroid46.9%Dexamethasone100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
2 NIH research awards on record, funded 2015–2022 per NIH RePORTER. The latest:
- Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC
Johns Hopkins University
FY2022$599,374U01CA231776 - Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC
Johns Hopkins University
FY2022$368,438U01CA231776 - Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC
Johns Hopkins University
FY2021$598,229U01CA231776
Congress activity
Updated 23 Oct 2026
57 congress contributions (2011–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 110: Clinical utility of landmark ctDNA molecular response as an early indicator of immunotherapy outcomes in lung cancer.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- TNIK Overexpression Is Sufficient for Chemoradiation Resistance in Limited-Stage Small Cell Lung Cancer.
Molecular cancer therapeutics
Article2026 - Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.
Clinical cancer research
Article2026 - Inhibition of CDKs Enhances the Efficacy of Anti-EGFR Therapy in Chordoma.
Molecular cancer therapeutics
Article2026 - Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.
Cancer research communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaArticle1,110 citations2009
- 02Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449Article1,019 citations2009
- 03Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in MedulloblastomaArticle840 citations2009
- 04
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD (Sidney Kimmel Medical College / Thomas Jefferson University, 2000), corroborates NPI-registry credential M.D., PH.D.
2000verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member
American Association for Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member
International Association for the Study of Lung Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel Laheru, MD
Johns Hopkins University
Demosthenes G. Katritsis
Johns Hopkins University
Tanguy Seiwert, MD
Johns Hopkins University
Evan Lipson, MD
Johns Hopkins University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”